You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
綠葉製藥(02186.HK)授予南非第三大私營醫藥公司的思瑞康®於南非及其若干鄰國的獨家分銷和推廣權
格隆匯 02-10 08:04

格隆匯2月10日丨綠葉製藥(02186.HK)公佈,集團全資子公司—Luye Hong Kong Limited,與Cipla Limited,India全資子公司Cipla Medpro South Africa (Pty) Limited簽署了就思瑞康®和思瑞康緩釋片®在南非、納米比亞及博茨瓦那的獨家分銷和推廣協議。

公告顯示,思瑞康®(富馬酸喹硫平、速釋、IR)及思瑞康緩釋片®(緩釋製劑)乃具有抗抑鬱特性的非典型抗精神病(AAP)藥物。思瑞康®的主要病症是治療精神分裂症和躁鬱症。思瑞康緩釋片®在若干市場亦獲准用於抑鬱症和廣泛性焦慮症。

據悉,Cipla Medpro是南非第三大的私營醫藥公司。在其分銷和市場推廣領域廣闊網絡和豐富經驗的支持下,公司董事相信該產品將在南非及其鄰國取得強勁的增長。

除思瑞康系列產品外,集團還有多箇中樞神經系統在研項目,其中包括LY030049(用於精神分裂和雙向情感障礙症)、LY03003(用於帕金森病)、LY03005(用於抑鬱症的治療)、LY03010(用於精神分裂症和分裂情感性障礙的治療)、LY30410(用於中輕度阿茲海默症)和LY03012(用於慢性疼痛)等項目。上述在研產品在中國、美國、歐洲和日本等戰略市場註冊進展良好,未來計劃在這些國家上市並進一步擴展到全球市場。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account